Skip to main content

Table 2 Antiviral treatment status

From: Cross-sectional retrospective analysis of clinical characteristics of chronic hepatitis B patients with oral antiviral treatment in eastern China

Variable Total (n = 8309) Treatment duration  ≤ 24 months (n = 4275) Treatment duration  > 24 months (n = 4034) P value
Treatment duration (months) 24.00 (11.00–44.00) 11.00 (5.00–17.00) 46.00 (35.00–62.00)
ETV, n(%) 5960 (71.73) 2904 (67.93) 3056 (75.76)  < 0.001
TDF, n(%) 1348 (16.22) 1015 (23.74) 333 (8.25)  < 0.001
Others, n(%) 1001 (12.05) 356 (8.33) 645 (15.99)  < 0.001
LAM exposure, n(%) 1094 (13.17) 77 (1.80) 1017 (25.21)  < 0.001
Nucleotide analogue exposure n(%) 2556 (30.76) 1211 (28.33) 1345 (33.34)  < 0.001
  1. ETV entecavir, TDF tenofovir disoproxil fumarate, LAM lamivudine
\